Dapsone Use in Dermatology

Am J Clin Dermatol. 2024 Sep;25(5):811-822. doi: 10.1007/s40257-024-00879-8. Epub 2024 Jul 30.

Abstract

Dapsone, initially synthesized for textile dyeing, gained recognition in the 1930s for its antibacterial properties, leading to its utilization in dermatology for leprosy and dermatitis herpetiformis. Despite US Food and Drug Administration (FDA) approval for these conditions, dapsone's off-label uses have expanded, making it a valuable option in various dermatologic conditions. This review seeks to highlight the common uses of dapsone in its FDA indications and off-label indications. Diseases in which dapsone is considered first-line therapy or adjunctive therapy are reviewed, with highlights from the resources included. An overview of dapsone's pharmacokinetics, pharmacodynamics, indications, dosages, and safety profile are also reviewed. Dapsone's versatility and safety profile make it a cost-effective treatment option in dermatology, particularly for patients with limited access to specialized medications. Ongoing clinical trials are also described exploring dapsone's efficacy in novel dermatologic uses. Dapsone has been a valuable adjunctive therapy across various dermatologic conditions for years and evidence for its use continues to expand.

Publication types

  • Review

MeSH terms

  • Dapsone* / pharmacology
  • Dapsone* / therapeutic use
  • Dermatitis Herpetiformis / drug therapy
  • Humans
  • Leprostatic Agents / adverse effects
  • Leprostatic Agents / therapeutic use
  • Leprosy / drug therapy
  • Off-Label Use*
  • Skin Diseases / drug therapy
  • Treatment Outcome

Substances

  • Dapsone
  • Leprostatic Agents